Cargando…

Readmission Rates of Patients with Schizophrenia Treated with Depot Antipsychotics versus Oral Antipsychotics in a Community Hospital

This is a pilot study comparing the 30 and 60 day relapse rates for schizophrenic patients treated with long-acting injectable antipsychotics versus traditional oral antipsychotics in a community hospital setting. This is a retrospective cohort study and medical records were reviewed to gather data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Espiridion, Eduardo D, Lewandrowski, Callum, Shahriari, Shiva, Bestoyong, Dorothy F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2018
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389030/ https://www.ncbi.nlm.nih.gov/pubmed/30820394 http://dx.doi.org/10.7759/cureus.3775

Ejemplares similares

Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study
por: Ahmadkhaniha, Hamid-Reza, et al.
Publicado: (2014)

Neuroleptic Malignant Syndrome After Re-introduction of Atypical Antipsychotics in a COVID-19 Patient
por: Espiridion, Eduardo D, et al.
Publicado: (2021)

Treatment adherence and social functioning in patients diagnosed with schizophrenia and treated with antipsychotic depot medication
por: POPP, BIANCA-STEPHANIE, et al.
Publicado: (2014)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
por: Amato, Davide, et al.
Publicado: (2019)

Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
por: Koricanac, Aleksandra, et al.
Publicado: (2022)

Comparison of cost-effectiveness of long-acting depot injection antipsychotics and oral antipsychotics in patients with schizophrenia in a rural community in South India
por: Raghavan, Vijaya, et al.
Publicado: (2020)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Yin, Ping, et al.
Publicado: (2021)

Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
por: Ventriglio, Antonio, et al.
Publicado: (2019)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)

Brain Networks Reveal the Effects of Antipsychotic Drugs on Schizophrenia Patients and Controls
por: Towlson, Emma K., et al.
Publicado: (2019)

Antipsychotics-induced improvement of cool executive function in individuals living with schizophrenia
por: Si, Yajing, et al.
Publicado: (2023)

Physical health monitoring in antipsychotic depot clinic
por: Davies, Rebecca, et al.
Publicado: (2021)

Metabolic Syndrome Monitoring in Patients on Depot Antipsychotics
por: Ateem, Salah
Publicado: (2023)

Association of Serotonin(2c) Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia
por: Li, Jiang, et al.
Publicado: (2019)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis
por: Valencia Carlo, Yarmila Elena, et al.
Publicado: (2023)

Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder
por: Chou, Fabienne, et al.
Publicado: (2016)

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report
por: Izuhara, Muneto, et al.
Publicado: (2018)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
por: Yu, Zhi-min, et al.
Publicado: (2019)

Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia
por: Nicoletti, Ferdinando, et al.
Publicado: (2019)

Predictors for Antipsychotic Dosage Change in the First Year of Treatment in Schizophrenia Spectrum and Bipolar Disorders
por: Ringen, Petter Andreas, et al.
Publicado: (2019)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics
por: Hori, Hikaru, et al.
Publicado: (2022)

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2022)

Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany
por: Potempa, Christoph, et al.
Publicado: (2018)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

Proteomic Analysis of Plasma Markers in Patients Maintained on Antipsychotics: Comparison to Patients Off Antipsychotics and Normal Controls
por: Engelke, Rudolf, et al.
Publicado: (2022)

Gyrification Connectomes in Unmedicated Patients With Schizophrenia and Following a Short Course of Antipsychotic Drug Treatment
por: Nelson, Eric A., et al.
Publicado: (2018)

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy
por: Zhang, Xiaobin, et al.
Publicado: (2020)

Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?
por: Vasiliu, Octavian
Publicado: (2022)

The Pharmacodynamics of Antipsychotic Drugs in Women and Men
por: Seeman, Mary V.
Publicado: (2021)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
por: Peng, Xiaomei, et al.
Publicado: (2011)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia
por: Strømme, Maria F., et al.
Publicado: (2022)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Relationship between Brain-Derived Neurotrophic Factor and Schneiderian First Rank Symptoms in Antipsychotic-Naïve Schizophrenia
por: Kalmady, Sunil Vasu, et al.
Publicado: (2013)

Which Subgroup of First-Episode Schizophrenia Patients Can Remit During the First Year of Antipsychotic Treatment?
por: Cheng, Zhang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gh43shfvee7a8nqkcou7pta247